These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 10090731)
1. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Kingma PS; Burden DA; Osheroff N Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731 [TBL] [Abstract][Full Text] [Related]
2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
3. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121 [TBL] [Abstract][Full Text] [Related]
4. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance. Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317 [TBL] [Abstract][Full Text] [Related]
5. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide. Jiang X Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155 [TBL] [Abstract][Full Text] [Related]
6. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide. Leontiou C; Lakey JH; Austin CA Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234 [TBL] [Abstract][Full Text] [Related]
7. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Cline SD; Macdonald TL; Osheroff N Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572 [TBL] [Abstract][Full Text] [Related]
8. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance. Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602 [TBL] [Abstract][Full Text] [Related]
9. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Nitiss JL; Vilalta PM; Wu H; McMahon J Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059 [TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Vassetzky YS; Alghisi GC; Gasser SM Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829 [TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
12. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375 [TBL] [Abstract][Full Text] [Related]
13. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related]
14. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Nitiss JL; Liu YX; Hsiung Y Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128 [TBL] [Abstract][Full Text] [Related]
15. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Morgan SE; Cadena RS; Raimondi SC; Beck WT Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639 [TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979 [TBL] [Abstract][Full Text] [Related]
17. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080 [TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190. Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509 [TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide. DeVore RF; Corbett AH; Osheroff N Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]